MIRM Stock Forecast & Price Target

Mirum Pharmaceuticals Inc. has demonstrated significant revenue growth, with LIVMARLI achieving sales of $88.1 million in 2Q25, marking an approximate 87% increase year-over-year. This strong performance prompted management to raise its 2025 revenue guidance to a range of $490 million to $510 million, reflecting an upward adjustment of $57.5 million at the midpoint. Additionally, the company's total revenues for 2Q25 reached $127.8 million, an increase of 64% compared to the same period in the prior year, indicating robust commercial momentum and higher-than-expected adoption rates for LIVMARLI in treating Alagille syndrome and progressive familial intrahepatic cholestasis.

Mirum Pharmaceuticals Inc faces significant challenges due to the lack of composition of matter patent coverage for its drug maralixibat, relying instead on method of use and formulation patents, which may weaken its competitive position. The company's early-stage revenue growth is susceptible to unexpected competition and slower sales uptake, potentially hindering its path to profitability. In addition, substantial volatility in share prices is anticipated given the inherent risks associated with clinical trials and regulatory outcomes in the biotech sector, further contributing to a negative outlook on the company's stock.